Clinical determinants of the PR interval duration in Swiss middle-aged adults: The CoLaus/PsyCoLaus study.


Journal

Clinical cardiology
ISSN: 1932-8737
Titre abrégé: Clin Cardiol
Pays: United States
ID NLM: 7903272

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 26 09 2019
revised: 25 02 2020
accepted: 27 02 2020
pubmed: 25 4 2020
medline: 26 5 2021
entrez: 25 4 2020
Statut: ppublish

Résumé

Prolonged PR interval (PRi) is associated with adverse outcomes. However, PRi determinants are poorly known. We aimed to identify the clinical determinants of the PRi duration in the general population. Some clinical data are associated with prolonged PRi. Cross-sectional study conducted between 2014 and 2017. Electrocardiogram-derived PRi duration was categorized into normal or prolonged (>200 ms). Determinants were identified using stepwise logistic regression, and results were expressed as multivariable-adjusted odds ratio (OR) (95% confidence interval). A further analysis was performed adjusting for antiarrhythmic drugs, P-wave contribution to PRi duration, electrolytes (kalemia, calcemia, and magnesemia), and history of cardiovascular disease. Overall, 3655 participants with measurable PRi duration were included (55.6% females; mean age 62 ± 10 years), and 330 (9.0%) had prolonged PRi. Stepwise logistic regression identified male sex (OR 1.41 [1.02-1.97]); aging (65-74 years: OR 2.29 [1.61-3.24], and ≥ 75 years: OR 4.21 [2.81-6.31]); increased height (per 5 cm, OR 1.15 [1.06-1.25]); hypertension (OR 1.37 [1.06-1.77]); and hs troponin T (OR 1.67 [1.15-2.43]) as significantly and positively associated, and high resting heart rate (≥70 beats/min, OR 0.43 [0.29-0.62]) as negatively associated with prolonged PRi. After further adjustment, male sex, aging and increased height remained positively, and high resting heart rate negatively associated with prolonged PRi. Hypertension and hs troponin T were no longer associated. In a sample of the Swiss middle-aged population, male sex, aging and increased height significantly increased the likelihood of a prolonged PRi duration, whereas a high resting heart rate decreased it.

Sections du résumé

BACKGROUND BACKGROUND
Prolonged PR interval (PRi) is associated with adverse outcomes. However, PRi determinants are poorly known. We aimed to identify the clinical determinants of the PRi duration in the general population.
HYPOTHESIS OBJECTIVE
Some clinical data are associated with prolonged PRi.
METHODS METHODS
Cross-sectional study conducted between 2014 and 2017. Electrocardiogram-derived PRi duration was categorized into normal or prolonged (>200 ms). Determinants were identified using stepwise logistic regression, and results were expressed as multivariable-adjusted odds ratio (OR) (95% confidence interval). A further analysis was performed adjusting for antiarrhythmic drugs, P-wave contribution to PRi duration, electrolytes (kalemia, calcemia, and magnesemia), and history of cardiovascular disease.
RESULTS RESULTS
Overall, 3655 participants with measurable PRi duration were included (55.6% females; mean age 62 ± 10 years), and 330 (9.0%) had prolonged PRi. Stepwise logistic regression identified male sex (OR 1.41 [1.02-1.97]); aging (65-74 years: OR 2.29 [1.61-3.24], and ≥ 75 years: OR 4.21 [2.81-6.31]); increased height (per 5 cm, OR 1.15 [1.06-1.25]); hypertension (OR 1.37 [1.06-1.77]); and hs troponin T (OR 1.67 [1.15-2.43]) as significantly and positively associated, and high resting heart rate (≥70 beats/min, OR 0.43 [0.29-0.62]) as negatively associated with prolonged PRi. After further adjustment, male sex, aging and increased height remained positively, and high resting heart rate negatively associated with prolonged PRi. Hypertension and hs troponin T were no longer associated.
CONCLUSION CONCLUSIONS
In a sample of the Swiss middle-aged population, male sex, aging and increased height significantly increased the likelihood of a prolonged PRi duration, whereas a high resting heart rate decreased it.

Identifiants

pubmed: 32329928
doi: 10.1002/clc.23356
pmc: PMC7299001
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

614-621

Subventions

Organisme : Faculty of Biology and Medicine of Lausanne
Organisme : GlaxoSmithKline
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 3200B0-105993
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 3200B0-118308
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 33CS30-139468
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 33CS30-148401
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 33CSCO-122661

Informations de copyright

© 2020 The Authors. Clinical Cardiology published by Wiley Periodicals, Inc.

Références

Circulation. 2002 Dec 17;106(25):3143-421
pubmed: 12485966
Heart. 2016 May;102(9):672-80
pubmed: 26879241
Clin Cardiol. 2017 Oct;40(10):865-872
pubmed: 28605034
Heart Rhythm. 2014 Jan;11(1):93-8
pubmed: 24096163
Eur J Cardiovasc Prev Rehabil. 2008 Aug;15(4):402-8
pubmed: 18677163
J Hypertens. 2006 Apr;24(4):603-10
pubmed: 16531784
Heart. 2018 Jun;104(11):904-911
pubmed: 29127183
Eur Heart J. 2003 Jun;24(11):987-1003
pubmed: 12788299
Europace. 2015 Jun;17(6):978-85
pubmed: 25164430
J Mol Cell Cardiol. 2006 Jul;41(1):97-107
pubmed: 16765374
Am J Med. 1964 Nov;37:742-8
pubmed: 14237429
BMC Cardiovasc Disord. 2008 Mar 17;8:6
pubmed: 18366642
Br J Sports Med. 2009 Sep;43(9):669-76
pubmed: 19734501
Cardiovasc Drugs Ther. 2009 Jun;23(3):249-54
pubmed: 19184388
Eur Heart J. 2014 Jan;35(2):123-9
pubmed: 23677846
Circulation. 1954 Sep;10(3):384-400
pubmed: 13190611
Circ Arrhythm Electrophysiol. 2017 Jan;10(1):
pubmed: 28039282
J Physiol. 2018 Apr 1;596(7):1137-1151
pubmed: 29274077
Am Heart J. 2014 Feb;167(2):150-159.e1
pubmed: 24439975
Can J Cardiol. 2017 May;33(5):674-681
pubmed: 28449838
Clin Exp Pharmacol Physiol. 2017 Dec;44 Suppl 1:55-63
pubmed: 28316086
J Am Coll Cardiol. 2017 Aug 29;70(9):1183-1192
pubmed: 28838369
JAMA. 2009 Jun 24;301(24):2571-7
pubmed: 19549974
Eur Heart J. 2012 Nov;33(21):2709-17
pubmed: 22977225
Circ Arrhythm Electrophysiol. 2013 Feb;6(1):84-90
pubmed: 23243193
Epidemiol Prev. 2014 Sep-Oct;38(5):335-41
pubmed: 25387748
Clin Cardiol. 1984 Jan;7(1):6-13
pubmed: 6705291
Clin Cardiol. 2020 Jun;43(6):614-621
pubmed: 32329928
Pacing Clin Electrophysiol. 2001 Jan;24(1):16-21
pubmed: 11227963
Circulation. 2017 Apr 18;135(16):1494-1505
pubmed: 28159799

Auteurs

Marylène Bay (M)

Department of Medicine, Internal Medicine, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

Peter Vollenweider (P)

Department of Medicine, Internal Medicine, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

Pedro Marques-Vidal (P)

Department of Medicine, Internal Medicine, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

Federica Bocchi (F)

Department of Medicine, Internal Medicine, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

Etienne Pruvot (E)

Department of Heart and Vessels, Service of Cardiology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

Jürg Schläpfer (J)

Department of Heart and Vessels, Service of Cardiology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH